Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes

Kidney International

Volumn 87, Issue 3, 2015, Pages 649-659

  Papademetriou, Vasilios ^a   Lovato, Laura ^b   Doumas, Michael ^c   Nylen, Eric ^c   Mottl, Amy ^d   Cohen, Robert M ^e,f   Applegate, William B ^b   Puntakee, Zubin ^g   Yale, Jean Francois ^h   Cushman, William C ⁱ  

^a GEORGETOWN UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^h Royal Victoria Hospital Barrie   (Canada)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cardiovascular morbidity; chronic kidney disease; intensive glycemic therapy; mortality; type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POPULATION RISK; PRIORITY JOURNAL; RISK ASSESSMENT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84928592111     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.296     Document Type: Article

References (33)

1. De Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011; 305: 2532-2539
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298: 2038-2048
3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-1305
4. Roderick PJ, Atkins RJ, Smeeth L, et al. CKD and mortality risk in older people: a community-based population study in the United Kingdom. Am J Kidney Dis. 2009; 53: 950-960
5. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-Analysis. Lancet. 2010; 375: 2073-2081
6. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality A collaborative meta-Analysis of high-risk population cohorts. Kidney Int. 2011; 79: 1341-1352
7. KDIGO. 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013; 3: S1-150
8. So W, Kong A, Ma R, et al. Glomerular filtration rate, cardiorenal endpoints, and all-cause mortality in type 2 diabetic patients. Diabetes Care. 2006; 29: 2046-2052
9. Bruno G, Merletti F, Bargero G, et al. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia. 2007; 50: 941-948
10. Targher G, Zoppini G, Chonchol M, et al. Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutr Metab Cardiovasc Dis. 2011; 21: 294-301
11. Yokoyama H, Araki S, Haneda M, et al. Chronic kidney disease categories and renal cardiovascular outcomes in Type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study. Diabetologia. 2012; 55: 1911-1918
12. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009; 20: 1813-1821
13. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559
14. Patel A, MacMahon S, Chalmers J, et al. The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572
15. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-139
16. Lachin JM. Point: intensive glycemic control and mortality in ACCORD-A chance finding?. Diabetes Care. 2010; 33: 2719-2721
17. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004; 15: 1307-1315
18. Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as a cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005; 20: 1048-1056
19. Kannel WB, Stampfer MJ, Castelli WP, et al. The prognostic significance of proteinuria: the Framingham study. Am Heart J. 1985; 108: 1347-1352
20. Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease. Arch Intern Med. 2011; 171: 1920-1927
21. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycaemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 1121-1127
22. Snyder RW, Bernds JS. Use of insulin and oral hypoglycaemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004; 17: 365-370
23. Institute of Medicine of the National AcademiesIn: Aspden PA, Wolcott JA, Bootman JL, Cronenwett LR (eds)Committee on identifying and preventing medication errors: 'medication errors: incidence and cost'. Preventing Medication Errors: Quality Chasm Series. National Academies Press: Washington DC, Washington, USA, 2006; 105-142
24. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am. 2005; 89: 649-687
25. Hug BL, Witkowski DJ, Sox CM, et al. Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those excreted by the kidney. Kidney Int. 2009; 76: 1192-1198
26. Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med. 2011; 124: 993-996
27. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340: b4909
28. Seaquist ER, Miller ME, Bonds DE, et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care. 2012; 35: 409-414
29. Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010; 33: 983-990
30. Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010; 33: 1578-1584
31. Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010; 33: 721-727
32. ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1575-1585
33. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-1574